Skip to main content
Premium Trial:

Request an Annual Quote

Genomatica Licenses TeselaGen's Software for Microbial DNA Design

NEW YORK (GenomeWeb News) – Genomatica has signed a multi-year licensing agreement with TeselaGen Biotechnology that allows it to use TeselaGen's automated DNA cloning software for its microbial strain engineering projects.

Specifically, the partners said that Genomatica will use the software to develop proprietary organisms that will be used to produce chemicals from renewable feedstocks.

The companies also said that they will make enhancements to the software so that it can better meet Genomatica's objectives. TeselaGen offers a commercial cloud-based version of j5, a software package that was initially developed by researchers at the Joint BioEnergy Institute.

"Genomatica's deep expertise in microbial strain development is very valuable to TeselaGen as we develop our software to solve real problems faced by industrial biologists," Michael Fero, TeselaGen co-founder and CEO, said in a statement.

Fero added, "Our academic roots have given us a firm platform on which to build, but now we're focused on meeting the needs of industrial customers" making this Genomatica partnership "ideal from our perspective."

Financial details of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.